TR-701 200 mg + TR-701 300 mg + TR-701 400 mg
Phase 2Completed 0 watching 0 views this week⚡ Active
52
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Skin Diseases, Infectious
Conditions
Skin Diseases, Infectious, Skin Diseases, Bacterial
Trial Timeline
Sep 17, 2008 → Feb 24, 2009
NCT ID
NCT00761215About TR-701 200 mg + TR-701 300 mg + TR-701 400 mg
TR-701 200 mg + TR-701 300 mg + TR-701 400 mg is a phase 2 stage product being developed by Merck for Skin Diseases, Infectious. The current trial status is completed. This product is registered under clinical trial identifier NCT00761215. Target conditions include Skin Diseases, Infectious, Skin Diseases, Bacterial.
Hype Score Breakdown
Clinical
17
Activity
12
Company
10
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00761215 | Phase 2 | Completed |
Competing Products
20 competing products in Skin Diseases, Infectious